| ID | 1192 |
| Name of the vaccine | O-SPC/rBRU |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 18 to 49 years |
| Description of the vaccine | Shigella sonnei O-SP-core vaccine. |
| Name of the manufacturer | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Name of the manufacturing country | Israel |
| Year of manufacture | 2013 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | 71.1% efficacy in 3-4 year-old. No efficacy for recipients of S. flexneri 2a. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose. |
| Mechanism of action | IgG antibody specific immunity. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01369927 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|